Molecular, Cytogenetic, and Immunophenotypic Biomarkers in Acute Myeloid Leukemia: Current Evidence and Future Directions—A Narrative Review
Health Science Reports · 2026-10 · 9 (10)
DOI: 10.1002/hsr2.73393 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Science Reports, online erschienen am 13.10.2026. Verfasst von Emmanuel Ifeanyi Obeagu. Beteiligte Einrichtung: Division of Haematology, Department of Biomedical and Laboratory Science Africa University Mutare Zimbabwe. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy with variable clinical behavior and outcomes. Conventional morphology‐based classification is insufficient to capture this complexity, necessitating the use of molecular, cytogenetic, and immunophenotypic biomarkers for accurate diagnosis, risk stratification, and therapeutic guidance.
Objective
This narrative review aims to synthesize current evidence on molecular, cytogenetic, and immunophenotypic biomarkers in AML and to highlight their clinical relevance and emerging future directions.
Methods
A narrative review of the literature was conducted, focusing on key molecular mutations, cytogenetic abnormalities, and immunophenotypic profiles with established or emerging diagnostic, prognostic, and predictive value in AML.
Results
Molecular biomarkers such as FLT3 , NPM1 , CEBPA , IDH1/2 , and TP53 mutations play central roles in AML pathogenesis and prognostication. Cytogenetic abnormalities remain critical for risk classification, with favorable, intermediate, and adverse karyotypic profiles strongly influencing outcomes. Immunophenotypic biomarkers, assessed by multiparameter flow cytometry, are essential for diagnosis and minimal residual disease monitoring, providing powerful prognostic information. Integration of these biomarkers has significantly advanced precision medicine in AML.
Conclusion
Molecular, cytogenetic, and immunophenotypic biomarkers collectively underpin modern AML management. Continued integration of multi‐omics data and MRD‐guided strategies is expected to further refine personalized therapy and improve clinical outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Haematology, Department of Biomedical and Laboratory Science Africa University Mutare Zimbabwe.
- Department of Molecular Medicine and Haematology, Faculty of Health Sciences University of the Witwatersrand Johannesburg South Africa.
- Department of Hematology and Immunohematology Bahir Dar University Bahir Dar Ethiopia.
ORCID-Profile: Emmanuel Ifeanyi Obeagu
Zitieren
APA
Obeagu, E. I. (2026). Molecular, Cytogenetic, and Immunophenotypic Biomarkers in Acute Myeloid Leukemia: Current Evidence and Future Directions—A Narrative Review. Health Science Reports, 9(10). https://doi.org/10.1002/hsr2.73393
Vancouver
Obeagu EI. Molecular, Cytogenetic, and Immunophenotypic Biomarkers in Acute Myeloid Leukemia: Current Evidence and Future Directions—A Narrative Review. Health Science Reports. 2026;9(10). doi:10.1002/hsr2.73393
BibTeX
@article{Obeagu2026,
author = {Obeagu, Emmanuel Ifeanyi},
title = {Molecular, Cytogenetic, and Immunophenotypic Biomarkers in Acute Myeloid Leukemia: Current Evidence and Future Directions—A Narrative Review},
journal = {Health Science Reports},
year = {2026},
volume = {9},
number = {10},
doi = {10.1002/hsr2.73393}
}
EUVIMED